Genpact Stock Gains 13% in a Month: Here's What You Should Know

Genpact Limited G stock has gained 13.1% in a month, outperforming the industry’s 8.9% rally and the Zacks S&P 500 Composite's 3.6% return.

1-Month Share Price Performance

                                                                  Image Source: Zacks Investment Research

Let us delve deeper into the factors that have contributed to the company’s outperformance.

Growth Opportunity Paved by AI

Genpact’s Digital Smart Enterprise Process (SEP) is a patented approach that leverages AI to improve the performance of clients’ business processes. Digital SEPs reduce inefficiencies and raise process quality through advanced domain-specific digital technologies, Lean Six Sigma methodologies and experience-centric principles.

Genpact Cora, an automation-to-AI-based platform, combines the company’s proprietary automation, analytics and AI technologies into a single common platform, accelerating clients’ digital transformations. We are bullish on Genpact’s performance to move up the trajectory on the back of future AI advancements.

Balance Sheet Bolsters Liquidity

Genpact’s cash and equivalent balance was $517 million at the end of the second quarter of 2026 against a current debt of $26 million. Having said that, it is further bolstered by $72 million in operating cash during the second quarter of 2026 against an operating cash outflow of $24 million in the preceding quarter. Similarly, FCF recovered to $62 million from the previous quarter’s negative FCF of $47 million.

                                                                 Image Source: Zacks Investment Research

During the second quarter of 2026, Genpact enhanced its cash position, which enhanced its liquidity. This is further justified by its current ratio of 2, substantially above the industry benchmark of 1.52. A current ratio of more than 1 often indicates that the company will be able to easily pay off its short-term obligations.                                                             

                                                                 Image Source: Zacks Investment Research

Share Buyback & Dividends Raise Investor Morale

The company repurchased shares worth $298.2 million, $214.1 million, $225.4 million, $252.7 million and $225.5 million over 2021, 2022, 2023, 2024 and 2025, respectively, reflecting a steady commitment to enhancing shareholder value.

On a similar note, Genpact’s dividend payouts have risen from $80.5 million in 2021 to $91.8 million in 2022, $100 million in 2023, $108 million in 2024 and $100 million in 2025, underlining a disciplined capital return strategy. Persistent share repurchases enhance the bottom line, raising investor morale, while consistent dividend payments attract income-seeking investors.

Zacks Rank & Stocks to Consider

Genpact currently carries a Zacks Rank #3 (Hold).

Some higher-ranked stocks in the broader Zacks Computer and Technology sector are Arista Networks ANET and Applied Materials AMAT, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Arista Networks has a long-term earnings growth expectation of 26.1%. ANET delivered a trailing four-quarter earnings surprise of 8.9%, on average.

Applied Materials has a long-term earnings growth expectation of 36.7%. AMAT delivered a trailing four-quarter earnings surprise of 5.5%, on average.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research